03/09/2017

CORRECTION: NCCN has published updates to the NCCN Guidelines® for Hodgkin Lymphoma

CORRECTION: NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hodgkin Lymphoma. These NCCN Guidelines^® are currently available as Version 1.2017. 

• CHL Refractory Disease (HODG-15)
  • For those with Deauville 1-3 prior to HDT/ASCR, the following maintenance therapy option after HDT/ASCR has been revised: “Consider brentuximab vedotin for 1 y if primary refractory or extranodal disease or relapse < 12 months following primary therapy.”
  • For those with Deauville 4 prior to HDT/ASCR, the following maintenance therapy option after HDT/ASCR has been revised: “Strongly consider brentuximab vedotin for 1 y.”

The original NCCN Flash Update for the NCCN Guidelines for Hodgkin Lymphoma, Version 1.2017 was distributed on Friday, March 3, 2017.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.